These organizations offer information and support for people living with wet AMD.
These organizations offer information and support for people living with wet AMD.
Prevent Blindness is the nation’s leading volunteer eye health and safety organization, dedicated to preventing blindness and preserving sight. Prevent Blindness promotes access to eye care, education, empowerment, and support for those with vision loss due to eye disease.
BrightFocus Foundation is a leading private funder of scientific research and public awareness to end macular degeneration, glaucoma, and Alzheimer’s disease.
Established in 1971, the Foundation Fighting Blindness is the world’s leading organization committed to finding treatments and cures for blinding retinal diseases.
Macular Degeneration Support is a strong voice and a principal resource for senior adults who are living with low vision. The organization has been serving thousands of people worldwide since 1994.
These organizations offer information and support for caregivers supporting people living with wet AMD.
Supporting a loved one can be a lot—to give your loved one the best care, it’s also important to take care of yourself. See the resources below for information to help as you care for a loved one living with a serious eye condition
The National Alliance for Caregiving
An organization committed to helping the families and friends of those with health care needs through research, advocacy, and innovation.
A support organization with the purpose of improving the quality of life for caregivers and those who receive care.
A publication dedicated to providing information, support, and guidance for families and professional caregivers.
When someone finds out they have wet AMD, they may feel overwhelmed and scared about their treatment. You can play an important role in helping manage their vision challenges and easing their concerns.
Around the home:
Keeping up communication:
An extra set of eyes and ears:
SUSVIMO® can offer your loved one continuous delivery of wet AMD treatment
Providing care for a loved one can be overwhelming. Be sure to take time to care for your own health and well-being, with the following tips in mind:
This information is provided as a resource for you. We do not endorse or show preference for any particular organization. The organizations in this list are not the only ones that might be able to help you.
This downloadable brochure can help to keep information close by about how SUSVIMO can help you get the most out of your treatment.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.